News Image

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

By Mill Chart

Last update: Apr 19, 2024

Uncover the potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that our stock screener found to be reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. We'll examine each aspect in detail.

Growth Analysis for NASDAQ:CORT

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:CORT has received a 7 out of 10:

  • CORT shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.03%.
  • Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 13.94% on average per year.
  • CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.28% yearly.
  • Based on estimates for the next years, CORT will show a quite strong growth in Revenue. The Revenue will grow by 14.98% on average per year.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Deciphering NASDAQ:CORT's Valuation Rating

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:CORT has achieved a 6 out of 10:

  • 83.16% of the companies in the same industry are more expensive than CORT, based on the Price/Earnings ratio.
  • 81.12% of the companies in the same industry are more expensive than CORT, based on the Price/Forward Earnings ratio.
  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CORT indicates a rather cheap valuation: CORT is cheaper than 80.10% of the companies listed in the same industry.
  • CORT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CORT is cheaper than 83.16% of the companies in the same industry.
  • CORT has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as CORT's earnings are expected to grow with 29.87% in the coming years.

Assessing Health Metrics for NASDAQ:CORT

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:CORT, the assigned 9 reflects its health status:

  • CORT has an Altman-Z score of 15.20. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 15.20, CORT belongs to the top of the industry, outperforming 92.35% of the companies in the same industry.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • A Current Ratio of 4.39 indicates that CORT has no problem at all paying its short term obligations.
  • CORT has a Current ratio of 4.39. This is in the better half of the industry: CORT outperforms 60.71% of its industry peers.
  • A Quick Ratio of 4.31 indicates that CORT has no problem at all paying its short term obligations.
  • CORT has a Quick ratio of 4.31. This is in the better half of the industry: CORT outperforms 61.73% of its industry peers.

How do we evaluate the Profitability for NASDAQ:CORT?

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:CORT has earned a 8 out of 10:

  • CORT has a better Return On Assets (17.08%) than 96.94% of its industry peers.
  • The Return On Equity of CORT (20.95%) is better than 92.35% of its industry peers.
  • CORT has a Return On Invested Capital of 17.91%. This is amongst the best in the industry. CORT outperforms 95.41% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for CORT is significantly above the industry average of 16.40%.
  • CORT has a better Profit Margin (22.01%) than 93.88% of its industry peers.
  • CORT's Operating Margin of 22.26% is amongst the best of the industry. CORT outperforms 89.80% of its industry peers.
  • Looking at the Gross Margin, with a value of 98.66%, CORT belongs to the top of the industry, outperforming 99.49% of the companies in the same industry.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

Check the latest full fundamental report of CORT for a complete fundamental analysis.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/30/2024, 7:00:00 PM)

After market: 23.32 0 (0%)

23.32

-0.05 (-0.21%)

CORT News

News Image2 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 4 CATALYST Trial
News Image6 days ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
News Image6 days ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter...

News Image8 days ago - Market News VideoNotable Monday Option Activity: RIOT, SIG, CORT
News Image9 days ago - Corcept Therapeutics IncorporatedCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
News Image12 days ago - ChartmillWhile growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

News Image16 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
News Image16 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image23 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
News Imagea month ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
News Imagea month ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Imagea month ago - Market News VideoNotable Monday Option Activity: GME, LULU, CORT
CORT Links
Follow us for more